Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19

• Temistocles Diaz,
• Temistocles Diaz,
• Barry H. Trachtenberg,
• Samuel J. K. Abraham,
• Samuel J. K. Abraham,
• Samuel J. K. Abraham,
• Rao KosagiSharaf,
• Armando A. Durant-Archibold,
• Armando A. Durant-Archibold

Affiliations

Temistocles Diaz

Internal Medicine-Interventional Cardiology, Department of Cardiology, Punta Pacifica Hospital, Affiliate of John Hopkins Medicine International, Panama City, Panama

Temistocles Diaz

Biomedicine Research Unit, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT Asociation of Public Interest), Panama City, Panama

Barry H. Trachtenberg

Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States

Samuel J. K. Abraham

Department of Surgery & Centre for Advancing Clinical Research (CACR), Yamanashi University, Chuo, Japan

Samuel J. K. Abraham

Edogawa Evolutionary Laboratory of Science (EELS), Edogawa Hospital, Tokyo, Japan

Samuel J. K. Abraham

The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India

Rao KosagiSharaf

Biomedicine Research Unit, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT Asociation of Public Interest), Panama City, Panama

Armando A. Durant-Archibold

Biomedicine Research Unit, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT Asociation of Public Interest), Panama City, Panama

Armando A. Durant-Archibold

Department of Biochemistry, College of Natural, Exact Science and Technology, Universidad de Panama, Panama City, Panama